Exacerbations · children with chronic asthma
It is very uncertain whether ciclesonide changes patients with exacerbations Number of patients with exacerbations compared with budesonide (dose ratio 1:2) (very low certainty).
1 finding from 1 review
Adverse events Number of patients with adverse events · children with chronic asthma
1 finding from 1 review
Asthma symptoms · children with chronic asthma
1 finding from 1 review
Exacerbations · children with chronic asthma
It is very uncertain whether ciclesonide changes patients with exacerbations Number of patients with exacerbations compared with fluticasone (dose ratio 1:1) (very low certainty).
1 finding from 1 review
Adverse events Number of patients with adverse events · children with chronic asthma
1 finding from 1 review
Asthma symptoms · children with chronic asthma
1 finding from 1 review
Exacerbations · children with chronic asthma
It is very uncertain whether ciclesonide changes patients with exacerbations Number of patients with exacerbations compared with fluticasone (dose ratio 1:2) (very low certainty).
1 finding from 1 review
Adverse events Number of patients with adverse events · children with chronic asthma
It is very uncertain whether ciclesonide changes adverse events Number of patients with adverse events compared with fluticasone (dose ratio 1:2) (very low certainty).
1 finding from 1 review
Hospital admissions · patients with acute asthma
ICS may leads to lower hospital admission compared with placebo (low certainty).
1 finding from 1 review
FEV1 (L) · patients with acute asthma
ICS showed no clear difference in FEV1 at 1 hour compared with placebo (low certainty).
1 finding from 1 review
FEV1 · patients with acute asthma
ICS showed no clear difference in FEV1 at 3 to 4 hours compared with placebo (moderate certainty).
1 finding from 1 review
Nausea and vomiting · patients with acute asthma
ICS showed no clear difference in adverse effects ‐ nausea/vomiting compared with placebo (low certainty).
1 finding from 1 review
Hospital admissions · patients with acute asthma
ICS showed no clear difference in hospital admission compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Asthma relapse1at 20 to 24 days · predominantly adults with acute asthma following emergency department discharge
Any ICS plus oral corticosteroid showed no clear difference in asthma relapse1at 20 to 24 days compared with oral corticosteroid (high certainty).
1 finding from 1 review
Hospital admissions · predominantly adults with acute asthma following emergency department discharge
Any ICS plus oral corticosteroid showed no clear difference in hospital admission compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Hoarseness at 20 to 24 days · predominantly adults with acute asthma following emergency department discharge
Any ICS plus oral corticosteroid showed no clear difference in hoarseness at 20 to 24 days compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Asthma relapse1at 16 to 21 days · patients with acute asthma following emergency department discharge
Any ICS showed no clear difference in asthma relapse1at 16 to 21 days compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Hospital admissions · patients with acute asthma following emergency department discharge
Any ICS showed no clear difference in hospital admission compared with oral corticosteroid (moderate certainty).
1 finding from 1 review
Hoarseness at 16 to 21 days · patients with acute asthma following emergency department discharge
Any ICS showed no clear difference in hoarseness at 16 to 21 days compared with oral corticosteroid (low certainty).
1 finding from 1 review
PEF (L/min) · patients with adults with acute asthma
Aminophylline showed no clear difference in PEF (L/min) ‐ at 60 min compared with placebo (low certainty).
1 finding from 1 review